EpiVax unveils a new vaccine

EpiVax Inc., a Providence-based biotechnology firm, last week announced it has developed a promising vaccine against tularemia. In animal studies at Rhode Island Hospital, the firm said, its TuliVaxTM protected against lethal doses of the disease. Stephen Gregory, an associate professor at Brown University's School of Medicine, used mice with "humanized" immune systems; the mice…

Register to keep reading or subscribe today and receive unlimited access.
Register Now Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

No posts to display